IL6 and colon adenocarcinoma: We have previously demonstrated that the JAK inhibitors ruxolitinib and tofacitinib suppress adipose wasting by blocking systemic and local levels of IL-6 family cytokines in the allotransplanted C26c20 colon adenocarcinoma in vivo cachexia model, which is syngeneic to Balb/c mice (15).